Rei Okada1,2, Hideaki Shimada3,4, Yuichiro Otsuka1, Masaru Tsuchiya1, Jun Ishii1, Toshio Katagiri1, Tetsuya Maeda1, Yoshihisa Kubota1, Tetsuo Nemoto5, Hironori Kaneko1,2. 1. Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-Ku, Tokyo, 143-8541, Japan. 2. Department of Clinical Oncology, Graduate School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-Ku, Tokyo, 143-8541, Japan. 3. Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-Ku, Tokyo, 143-8541, Japan. hideaki.shimada@med.toho-u.ac.jp. 4. Department of Clinical Oncology, Graduate School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-Ku, Tokyo, 143-8541, Japan. hideaki.shimada@med.toho-u.ac.jp. 5. Department of Clinical Pathology, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-Ku, Tokyo, 143-8541, Japan.
Abstract
PURPOSE: Only a few studies have evaluated the clinicopathological significance of the p53 protein expression and s-p53-Abs level in patients with cholangiocarcinoma. We therefore analyzed the clinicopathological and prognostic significance of s-p53-Abs in patients with extrahepatic cholangiocarcinoma. METHODS: We prospectively evaluated s-p53-Abs levels before and after surgery in 61 patients with extrahepatic cholangiocarcinoma to determine the relationship between clinicopathological factors and the prognostic significance of s-p53-Abs. RESULTS: Among a total of 61 primary extrahepatic cholangiocarcinoma cases, 23% were positive for s-p53-Abs. Combination of s-p53-Abs with the conventional serum markers carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) significantly increased the rate of positive extrahepatic cholangiocarcinoma cases (57% for CEA and/or CA19-9 vs. 75% for CEA and/or CA19-9 and/or s-p53-Abs, P = 0.035). There were no significant differences in clinicopathological factors between the p53-seropositive and p53-seronegative patients. An immunohistochemical analysis showed the presence of significant associations between the intensity (P = 0.003) and extent (P = 0.001) of p53 immunoreactivity and p53-seropositivitly. Although s-p53-Abs was not a significant prognostic factor for the survival in either univariate or multivariate analyses, p53 immunoreactivity was independently associated with a poor survival. Among patients positive for s-p53-Abs before surgery, the s-p53-Abs levels were reduced after surgery in most. CONCLUSION: These findings suggested that s-p53-Abs might be associated with p53 immunoreactivity. In addition, s-p53-Abs may be useful for a diagnosis, but was not useful for predicting tumor recurrence or the survival. This study was registered as UMIN000014530.
PURPOSE: Only a few studies have evaluated the clinicopathological significance of the p53 protein expression and s-p53-Abs level in patients with cholangiocarcinoma. We therefore analyzed the clinicopathological and prognostic significance of s-p53-Abs in patients with extrahepatic cholangiocarcinoma. METHODS: We prospectively evaluated s-p53-Abs levels before and after surgery in 61 patients with extrahepatic cholangiocarcinoma to determine the relationship between clinicopathological factors and the prognostic significance of s-p53-Abs. RESULTS: Among a total of 61 primary extrahepatic cholangiocarcinoma cases, 23% were positive for s-p53-Abs. Combination of s-p53-Abs with the conventional serum markers carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) significantly increased the rate of positive extrahepatic cholangiocarcinoma cases (57% for CEA and/or CA19-9 vs. 75% for CEA and/or CA19-9 and/or s-p53-Abs, P = 0.035). There were no significant differences in clinicopathological factors between the p53-seropositive and p53-seronegative patients. An immunohistochemical analysis showed the presence of significant associations between the intensity (P = 0.003) and extent (P = 0.001) of p53 immunoreactivity and p53-seropositivitly. Although s-p53-Abs was not a significant prognostic factor for the survival in either univariate or multivariate analyses, p53 immunoreactivity was independently associated with a poor survival. Among patients positive for s-p53-Abs before surgery, the s-p53-Abs levels were reduced after surgery in most. CONCLUSION: These findings suggested that s-p53-Abs might be associated with p53 immunoreactivity. In addition, s-p53-Abs may be useful for a diagnosis, but was not useful for predicting tumor recurrence or the survival. This study was registered as UMIN000014530.
Authors: P Tangkijvanich; K Kasemsupatana; A Janchai; P Kullavanijaya; A Theamboonlers; Y Poovorawan Journal: Asian Pac J Allergy Immunol Date: 2000-09 Impact factor: 2.310
Authors: P Hammel; B Boissier; M T Chaumette; P Piedbois; N Rotman; J C Kouyoumdjian; R Lubin; J C Delchier; T Soussi Journal: Gut Date: 1997-03 Impact factor: 23.059
Authors: U Ribeiro; S D Finkelstein; A V Safatle-Ribeiro; R J Landreneau; M R Clarke; A Bakker; P A Swalsky; W E Gooding; M C Posner Journal: Cancer Date: 1998-07-01 Impact factor: 6.860